RhumbLine Advisers
PYXS icon

RhumbLine Advisers’s Pyxis Oncology PYXS Stock Holding History

RhumbLine Advisers’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-68,156
Closed -$66.8K – 4234
2025
Q1 		$66.8K Buy
68,156
+305
+0.4% +$407 ﹤0.01% 3501
2024
Q4 		$106K Buy
67,851
+3,423
+5% +$9.87K ﹤0.01% 3463
2024
Q3 		$236K Sell
64,428
-859
-1% -$3.01K ﹤0.01% 3152
2024
Q2 		$216K Buy
+65,287
New +$274K ﹤0.01% 3188

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RhumbLine Advisers's PYXS Position: Q2 2025 in Review

RhumbLine Advisers sold out of Pyxis Oncology (PYXS) in Q2 2025, closing a stake of 68,156 shares — an estimated $66.8K sold.

RhumbLine Advisers first reported a position in PYXS in Q2 2024 and held it in 4 quarters. The position peaked at $236K in Q3 2024. 74 funds tracked by Wall St. Rank hold PYXS as of Q2 2025.

  • RhumbLine Advisers reported no remaining Pyxis Oncology position as of Q2 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 68,156 Pyxis Oncology shares in Q2 2025, an estimated $66.8K.
  • RhumbLine Advisers first reported a position in Pyxis Oncology in Q2 2024 and held it in 4 quarters.
  • RhumbLine Advisers's Pyxis Oncology position peaked at $236K in Q3 2024.
  • 74 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.